Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient.
Sachpekidis C et al. Diagnostics (Basel). 2017 Dec 15;7(4). pii: E61. doi: 10.3390/diagnostics7040061.
Predictive value of 18 F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma.
Tu H et al. Eur J Haematol. 2017 Dec 11. doi: 10.1111/ejh.13006. [Epub ahead of print].
Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma.
Horger M et al. Skeletal Radiol. 2017 Dec 8. doi: 10.1007/s00256-017-2827-y. [Epub ahead of print].
Increased Circulating Plasma Cells detected by Flow Cytometry Predicts Poor Prognosis in Patients with Plasma Cell Myeloma.
Bae MH et al. Cytometry B Clin Cytom. 2017 Dec 8. doi: 10.1002/cyto.b.21606. [Epub ahead of print].
Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation.
Mosebach J et al. Haematologica. 2017 Dec 7. pii: haematol.2017.176073. doi: 10.3324/haematol.2017.176073. [Epub ahead of print].
Serum protein markers of clonal heterogeneity in myeloma.
Landgren O et al. Lancet Haematol. 2017 Dec;4(12):e565-e566. doi: 10.1016/S2352-3026(17)30216-8.